Table 2.
Studies from countries which have reported breakthrough COVID-19 infection post vaccination.
| Country | Vaccine and manufacturer | Total SARS-CoV-2 vaccine breakthrough infections | Asymptomatic or mild disease | Age | Deaths |
|---|---|---|---|---|---|
| USA [40] | BNT162b2 mRNA COVID-19 vaccine mRNA-1273 SARS-CoV-2 vaccine Ad26.COV2.S vaccine |
10,262 out of 101 million persons | 2725(27%) were asymptomatic; 995 (10%) hospitalized; and 160 (2%) patients died. | The median age of patients who died was 82 years | 28 (18%) decedents were asymptomatic or died from a cause unrelated to COVID-19. |
| USA [41] | Moderna COVID-19 vaccination | 22 out of 627 possible breakthrough infections ≥14 days after their second dose of vaccine. | Two thirds of persons were asymptomatic. A minority had mild to moderate COVID-19–like symptoms; two COVID-19–related hospitalizations and | 61.5 years | one death occurred. Yes, COVID-19 related |
| USA [42] | second dose of BNT162b2 (Pfizer–BioNTech) or mRNA-1273 (Moderna) vaccine | 2/417 2 women with vaccine breakthrough infection |
|||
| USA [43] | BNT162b2 (Pfizer–BioNTech) or mRNA-1273 (Moderna) vaccine | 379 tested positives for COVID-19 (0.05%.) | Data not available | health care workers in the study were young | No death |
| India [12] | (Covaxin, 28, Covishield, 85) | 113 vaccinated | Asymptomatic infection in 98. Among 15 having symptoms, 14 had mild disease and only 1 required hospitalization | All vaccine recipients were >45-year-old as per Indian vaccination regulations | No death |
| UK [44] | BNT162b2 (Pfizer–BioNTech) or mRNA-1273 (Moderna) vaccine | Among symptomatic patients (1823), 40% (729) developed covid-19 symptoms in 1st week and 19% (352) developed symptoms in 2nd week post-vaccination. | 2019 of 3842 were asymptomatic | 82 of the 113 deaths were in the high risk “frail elderly” group. | 113 died with COVID-19. |
| UK [45] | Pfizer-BioNTech (BNT162b2) and the Oxford-AstraZeneca (ChAdOx1 nCoV-19) | 3106 of 103,622 vaccinated tested positive for SARS-CoV-2 infection | Data not available | overall mean age of the vaccinated was higher than that of the general population (40·3 years)24 | Not mentioned |
| Israel [46] | BNT162b2 mRNA vaccine | 10,561 infections were documented (0.6 infections per 1000 person-days), | 43% were asymptomatic | Mean age was 45 years | 229 were severe cases of COVID-19, and 41 resulted in death. |
| India [47] | Covishield | 86 (18.65%) got infection in 461 study population | No data on asymptomatic. Disease was Mild in 69(80.2%), moderate in 10(11.62%), severe in 6(6.97%) and critical in 1(1.16%) | All health care workers | mortality was 1 out of 86 cases |
| USA [48] | either mRNA vaccine (Pfizer, Moderna) | Multicenter observational cohort analysis across eight hospitals among 11834 patients | 10880 unvaccinated, 825 partially vaccinated, and 129 fully vaccinated Emergency department patients. | Average age was 53.0 | death occurred in 384 (3.5% of 10880) Unvaccinated patients, 50 (6.1% of 825) Partially vaccinated patients, and 8 (6.2% of 129) Fully vaccinated patients. |
| Italy [49] | 2 doses of BNT162b2(Pfizer) | 33 breakthrough infections in 3694 health care workers | mildly symptomatic in 16 (48%) and asymptomatic in 17 (52% | All health care workers | Not available |
| India [50] | Covaxin or covishield | 37 (11.3%) infections in 325 worekrs | Most breakthrough infection cases (94.4%) were mild | Mean age of 29 years old health care workers | Not available |